Patents by Inventor Naoki Hosen
Naoki Hosen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230357390Abstract: Provided is an antibody effective in treating tumors and the like. The antibody recognizes an epitope that contains an N-glycosylation site of human CD98hc and that is exposed by inhibiting N-linked glycosylation.Type: ApplicationFiled: July 21, 2023Publication date: November 9, 2023Applicant: OSAKA UNIVERSITYInventors: Naoki Hosen, Haruo Sugiyama, Atsushi Kumanogoh
-
Publication number: 20220064287Abstract: Provided is an antibody effective in treating tumors and the like. The antibody recognizes an epitope that contains an N-glycosylation site of human CD98hc and that is exposed by inhibiting N-linked glycosylation.Type: ApplicationFiled: November 16, 2021Publication date: March 3, 2022Applicant: OSAKA UNIVERSITYInventors: Naoki HOSEN, Haruo SUGIYAMA, Atsushi KUMANOGOH
-
Publication number: 20220041735Abstract: Provided is an active ingredient of a pharmaceutical composition for treating myeloma. Specifically, provided is an antibody whose epitope is present in the region of the amino acid residue positions 20 to 109 of human integrin ?7.Type: ApplicationFiled: March 22, 2021Publication date: February 10, 2022Applicant: OSAKA UNIVERSITYInventors: Naoki HOSEN, Haruo SUGIYAMA, Atsushi KUMANOGOH, Junichi TAKAGI
-
Patent number: 10988540Abstract: Provided is an active ingredient of a pharmaceutical composition for treating myeloma. Specifically, provided is an antibody whose epitope is present in the region of the amino acid residue positions 20 to 109 of human integrin ?7.Type: GrantFiled: June 18, 2020Date of Patent: April 27, 2021Assignee: OSAKA UNIVERSITYInventors: Naoki Hosen, Haruo Sugiyama, Atsushi Kumanogoh, Junichi Takagi
-
Publication number: 20200385474Abstract: Provided is an active ingredient of a pharmaceutical composition for treating myeloma. Specifically, provided is an antibody whose epitope is present in the region of the amino acid residue positions 20 to 109 of human integrin ?7.Type: ApplicationFiled: June 18, 2020Publication date: December 10, 2020Applicant: OSAKA UNIVERSITYInventors: Naoki HOSEN, Haruo SUGIYAMA, Atsushi KUMANOGOH, Junichi TAKAGI
-
Publication number: 20200283533Abstract: Provided is an active ingredient of a pharmaceutical composition for treating myeloma. Specifically, provided is an antibody whose epitope is present in the region of the amino acid residue positions 20 to 109 of human integrin ?7.Type: ApplicationFiled: March 4, 2020Publication date: September 10, 2020Applicant: OSAKA UNIVERSITYInventors: Naoki HOSEN, Haruo SUGIYAMA, Atsushi KUMANOGOH, Junichi TAKAGI
-
Patent number: 10654931Abstract: Provided is an active ingredient of a pharmaceutical composition for treating myeloma. Specifically, provided is an antibody whose epitope is present in the region of the amino acid residue positions 20 to 109 of human integrin ?7.Type: GrantFiled: August 2, 2016Date of Patent: May 19, 2020Assignee: OSAKA UNIVERSITYInventors: Naoki Hosen, Haruo Sugiyama, Atsushi Kumanogoh, Junichi Takagi
-
Publication number: 20180230212Abstract: Provided is an antibody effective in the treatment of tumors and the like. An antibody that includes an N-type glycosylation site of human CD98hc and recognizes an epitope exposed by inhibition of N-type glycosylation modification.Type: ApplicationFiled: August 9, 2016Publication date: August 16, 2018Applicant: OSAKA UNIVERSITYInventors: Naoki HOSEN, Haruo SUGIYAMA, Atsushi KUMANOGOH
-
Publication number: 20180230216Abstract: Provided is an active ingredient of a pharmaceutical composition for treating myeloma. Specifically, provided is an antibody whose epitope is present in the region of the amino acid residue positions 20 to 109 of human integrin ?7.Type: ApplicationFiled: August 2, 2016Publication date: August 16, 2018Applicant: OSAKA UNIVERSITYInventors: Naoki HOSEN, Haruo SUGIYAMA, Atsushi KUMANOGOH, Junichi TAKAGI
-
Patent number: 9097717Abstract: The present invention provides a therapeutic agent, for diseases in which neoplastic proliferation of plasma cells occurs, which is characterized by containing an anti-human CD48 monoclonal antibody and having cellular cytotoxicity to cells expressing human CD48; and the monoclonal antibody. In addition, the present invention provides a method for screening an active ingredient of a therapeutic agent for diseases in which neoplastic proliferation of plasma cells occurs, the method including the following processes: (1) a process of sorting a substance that binds specifically to human CD48; and (2) a process of sorting a substance having cellular cytotoxicity.Type: GrantFiled: April 9, 2010Date of Patent: August 4, 2015Assignee: OSAKA UNIVERSITYInventors: Naoki Hosen, Haruo Sugiyama
-
Patent number: 8232071Abstract: Acute myeloid leukemia stem cells (AMLSC) are identified. The cells can be prospectively isolated or identified from patient samples, and are shown to possess the unique properties of cancer stem cells in functional assays for cancer stem cell self-renewal and differentiation, and in cancer diagnosis.Type: GrantFiled: June 16, 2010Date of Patent: July 31, 2012Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Irving L. Weissman, Naoki Hosen
-
Publication number: 20120045446Abstract: The present invention provides a therapeutic agent, for diseases in which neoplastic proliferation of plasma cells occurs, which is characterized by containing an anti-human CD48 monoclonal antibody and having cellular cytotoxicity to cells expressing human CD48; and the monoclonal antibody. In addition, the present invention provides a method for screening an active ingredient of a therapeutic agent for diseases in which neoplastic proliferation of plasma cells occurs, the method including the following processes: (1) a process of sorting a substance that binds specifically to human CD48; and (2) a process of sorting a substance having cellular cytotoxicity.Type: ApplicationFiled: April 9, 2010Publication date: February 23, 2012Applicant: OSAKA UNIVERSITYInventors: Naoki Hosen, Haruo Sugiyama
-
Publication number: 20100255575Abstract: Acute myeloid leukemia stem cells (AMLSC) are identified. The cells can be prospectively isolated or identified from patient samples, and are shown to possess the unique properties of cancer stem cells in functional assays for cancer stem cell self-renewal and differentiation, and in cancer diagnosis.Type: ApplicationFiled: June 16, 2010Publication date: October 7, 2010Inventors: Irving L. Weissman, Naoki Hosen
-
Patent number: 7767410Abstract: Acute myeloid leukemia stem cells (AMLSC) are identified. The cells can be prospectively isolated or identified from patient samples, and are shown to possess the unique properties of cancer stem cells in functional assays for cancer stem cell self-renewal and differentiation, and in cancer diagnosis.Type: GrantFiled: December 7, 2007Date of Patent: August 3, 2010Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Irving L. Weissman, Naoki Hosen
-
Publication number: 20080187950Abstract: Acute myeloid leukemia stem cells (AMLSC) are identified. The cells can be prospectively isolated or identified from patient samples, and are shown to possess the unique properties of cancer stem cells in functional assays for cancer stem cell self-renewal and differentiation, and in cancer diagnosis.Type: ApplicationFiled: December 7, 2007Publication date: August 7, 2008Inventors: Irving L. Weissman, Naoki Hosen
-
Methods for Separating Hepatic, Endothelial, or Hematopoietic Progenitor Cells From Cell Populations
Publication number: 20080003637Abstract: The present inventors succeeded in FACS-sorting viable WT1-expressing cells, and also discovered that WT1 expression in mouse fetal liver cells serves as a common molecular marker of hepatic, endothelial, and hematopoietic progenitor cells. Based on the present invention, hepatic, endothelial, and hematopoietic progenitor cells can be separated or detected using the WT1 gene expression level as an indicator.Type: ApplicationFiled: March 28, 2005Publication date: January 3, 2008Inventors: Haruo Sugiyama, Naoki Hosen, N.D. Hastie